Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Aug
21
Today In Oncology
Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk
Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses
FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices
Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality
INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo